Keyphrases
Childhood Acute Lymphoblastic Leukemia
71%
Survivors
69%
Pediatric
56%
Relapsed or Refractory
54%
Chemotherapy-only
51%
Pediatric Patients
51%
Acute Myeloid Leukemia
44%
Paediatric Strategy Forum
44%
European Medicines Agency
44%
Confidence Interval
40%
Posterior Fossa Tumor
33%
Tumor
33%
Medicinal Product Development
30%
Speech Impairment
30%
Children with Cancer
28%
Pediatric Oncology
26%
Acute Lymphoblastic Leukemia
26%
Central Nervous System Tumors
26%
Clinical Trials
22%
Chemotherapy
22%
Progression-free Survival
21%
Young Cancer Patients
20%
Cranial Irradiation
20%
Gemtuzumab Ozogamicin
20%
Naxitamab
20%
Pediatric Hematology
20%
Diffuse Intrinsic Pontine Glioma
20%
18F-fluoro-ethyl-tyrosine
20%
European multicentre Study
20%
Childhood Brain Tumors
20%
Mitogen-activated Protein Kinase
20%
Dose-limiting Toxicity
19%
Brain Tumor
19%
High-risk Neuroblastoma
18%
Residual Tumor
18%
Hematopoietic Stem Cell Transplantation
17%
Overall Survival
17%
Phase II Trial
17%
Diagnostic Accuracy
16%
Risk Factors
16%
Working Diagnosis
16%
Late Effects
16%
Childhood Cancer
15%
Pediatric Cancer
15%
Preadolescent children
15%
Cerebellar mutism Syndrome
14%
Long-term Survivors
14%
BCP-ALL
14%
Pediatric Low-grade Glioma
14%
Leukemia
14%
Medicine and Dentistry
Pediatrics
100%
Neoplasm
69%
Medicine
56%
Acute Myeloid Leukemia
54%
Malignant Neoplasm
50%
Adolescent
48%
Childhood Cancer
35%
Acute Lymphoblastic Leukemia
35%
Clinical Trial
34%
Disease
34%
Pediatrics Patient
33%
Posterior Cranial Fossa Tumor
33%
Ganglioglioma
32%
Speech Disorder
30%
Central Nervous System Tumor
26%
Ganglioneuroblastoma
25%
Adverse Event
25%
Diagnosis
24%
Overall Survival
23%
Mutism
21%
Medulloblastoma
21%
Pontine Glioma
20%
Fluorine-18
20%
Arm
20%
Magnetic Resonance Imaging
20%
Infusion
20%
Pediatric Oncology
20%
Pediatric Hematology
20%
Progression Free Survival
19%
Brain Tumor
18%
Positron Emission Tomography
16%
Cancer
16%
Speech Production
16%
Radiation Therapy
15%
Surgery
15%
Late Effect
15%
Targeted Therapy
14%
Diagnostic Accuracy
13%
Outpatient
13%
Solid Malignant Neoplasm
13%
Posterior Fossa
12%
Molecular Profiling
12%
Phosphotransferase Inhibitor
11%
Nodular Melanoma
11%
Bevacizumab
11%
Chimeric Antigen Receptor T-Cell
11%
Phosphotransferase
11%
Leukemia
10%
Mitogen-Activated Protein Kinase
10%
Neck
10%
